Scarica l'app Stockscreener
7.34
0.41%
-0.03
Dopo l'orario di chiusura:
7.39
0.05
+0.68%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VIR Giù?
Forum
Previsione
Vir Biotechnology Inc Borsa (VIR) Ultime notizie
State Street Corp Has $42.14 Million Position in Vir Biotechnology, Inc. (NASDAQ:VIR) - MarketBeat
Y Intercept Hong Kong Ltd Reduces Holdings in Vir Biotechnology, Inc. (NASDAQ:VIR) - MarketBeat
Vir Biotechnology CEO to Present at J.P. Morgan Healthcare Conference 2024 - StockTitan
Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Business Wire
Long Term Trading Analysis for (VIR) - Stock Traders Daily
Vir Biotechnology's SWOT analysis: stock poised for growth amid hepatitis breakthroughs - Investing.com
GlaxoSmithKline & Vir Biotechnology's Sotrovimab Antibody Cleared for Emergency Use in the U.S. - Oficjalny Portal Gminy Brzesko
Vir Biotechnology Could Be An Early Riser In 2025 With Oncology Data In January (VIR) - Seeking Alpha
Vir Biotechnology's drugs receive FDA and EMA nods - Investing.com India
Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta - BioSpace
Vir's Hepatitis Delta Treatment Earns FDA Breakthrough & EMA PRIME Status After Strong Trial Data - StockTitan
Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Acquired by Charles Schwab Investment Management Inc. - MarketBeat
(VIR) Trading Signals - Stock Traders Daily
Vir Biotechnology EVP vanina de Verneuil sells $624 in stock By Investing.com - Investing.com Canada
Vir Biotechnology EVP vanina de Verneuil sells $624 in stock - Investing.com
Vir Biotechnology (VIR) Trades Higher in Sympathy with Janux Therapeutics (JANX) - StreetInsider.com
Vir Biotechnology (NASDAQ:VIR) three-year losses have grown faster than shareholder returns have fallen, but the stock surges 12% this past week - Simply Wall St
Will Vir Biotechnology (NASDAQ:VIR) Spend Its Cash Wisely? - Yahoo Finance
Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN™ Masked T-Cell Engager Programs - BioSpace
Vir Biotechnology's SWOT analysis: stock poised for growth amid clinical progress - Investing.com
Vir Biotechnology to Participate in the 7th Annual Evercore ISI HealthCONx Conference - BioSpace
Vir Biotechnology CEO to Present at Evercore ISI HealthCONx Conference | VIR Stock News - StockTitan
Leerink Partnrs Has Pessimistic View of VIR FY2026 Earnings - MarketBeat
HC Wainwright Has Optimistic Outlook of VIR FY2024 Earnings - MarketBeat
Needham & Company LLC Reiterates Buy Rating for Vir Biotechnology (NASDAQ:VIR) - MarketBeat
Vir Biotechnology poised for outperformance, keeps buy rating on pipeline potential - Investing.com UK
Empowered Funds LLC Sells 163,723 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) - MarketBeat
500: Something went wrong - Investing.com India
Vir Biotechnology holds a virtual investor update - Nasdaq
Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency - BioSpace
Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program - BioSpace
VIRVir Biotechnology, Inc. Latest Stock News & Market Updates - StockTitan
Vir's Hepatitis Delta Drug Achieves 100% Response Rate in Phase 2 Trial | VIR Stock News - StockTitan
EMA grants orphan drug status to Vir Biotech hepatitis treatments - Investing.com
EMA grants orphan drug status to Vir Biotech hepatitis treatments By Investing.com - Investing.com Canada
Vir Biotechnology (VIR) Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency - StreetInsider.com
Vir Biotechnology stock hits 52-week low at $7.08 - Investing.com
Vir Biotechnology stock hits 52-week low at $7.08 By Investing.com - Investing.com UK
Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD the Liver Meeting - Marketscreener.com
Vir Biotechnology (NASDAQ:VIR) Shares Down 7.4%Here's Why - MarketBeat
(VIR) Proactive Strategies - Stock Traders Daily
What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday? - Yahoo Finance
Promising hepatitis B treatment data presented by Vir Biotechnology - Investing.com
Vir Biotechnology Inc. (VIR) Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations - StreetInsider.com
Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting - Business Wire
Baillie Gifford & Co. Reduces Position in Vir Biotechnology, Inc. (NASDAQ:VIR) - MarketBeat
Vir Biotechnology's EVP sells shares worth $44,453 - Investing.com India
Vir Biotechnology's EVP sells shares worth $44,453 By Investing.com - Investing.com UK
Vir Biotechnology EVP vanina de Verneuil sells $32,332 in shares - Investing.com India
Leerink Partnrs Has Negative Outlook of VIR FY2024 Earnings - MarketBeat
HC Wainwright Expects Lower Earnings for Vir Biotechnology - MarketBeat
Vir Biotechnology, Inc. (NASDAQ:VIR) Q3 2024 Earnings Call Transcript - MSN
Vir Biotechnology's Refocused Pipeline: Hepatitis And Oncology Could Still Pay Off (NASDAQ:VIR) - Seeking Alpha
VIR Biotechnology's SWOT analysis: stock poised for growth amid challenges - Investing.com India
VIR Biotechnology's SWOT analysis: stock poised for growth amid challenges By Investing.com - Investing.com Nigeria
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):